J. Larry Jameson Reappointed Head of Penn Medicine and Perelman School of Medicine
J. Larry Jameson has been reappointed executive vice president of the University of Pennsylvania for the Health System and dean of Penn’s Perelman School of Medicine.
The announcement was made today by Penn President Amy Gutmann and Provost Vincent Price. The reappointment, which will run through June 30, 2023, and is subject to approval by the Board of Trustees, follows a review of his first term by a consultative committee appointed by Gutmann and Price.
“We agree with the committee’s conclusion that Dean Jameson’s first term was one of significant accomplishment,” Gutmann said. “The Perelman School and Penn Medicine have seen impressive and continued progress under his leadership.”
“The committee,” Price said, “was enthusiastic and unanimous in its confidence that Dean Jameson has the skills to effectively address the varied opportunities and challenges he and the School will face in the years ahead and therefore to have a successful and productive second term.”
The committee found especially notable the comprehensive, inclusive and far-reaching strategic plan, developed with Jameson’s strong leadership and support. It also noted two overarching accomplishments of the dean’s that merit special mention: his abiding sense of University citizenship and his full embrace of the multi-dimensional and integrated mission of Penn Medicine.
During Jameson’s tenure to date, the University of Pennsylvania Health System has undergone transformative growth, adding Chester County Hospital and Lancaster General Health. New building projects on the Perelman School and Health System’s Philadelphia campus, including completion of the Henry A. Jordan M'62 Medical Education Center, have cemented the advanced infrastructure necessary to support forward-thinking academic and patient-care missions.
His strong emphasis on translational research has paved a path for Penn-developed therapies to get to patients more quickly. Jameson’s trail-blazing personalized medicine initiatives have accelerated progress in laboratories and provided fresh options for patients in need.